Valneva SE (VALN) Interest Expenses (2020 - 2026)
Valneva SE (VALN) reported Interest Expenses of -$6.0 million for Q1 2026, up 5.21% on a YoY basis from -$5.7 million in Q1 2025, and down 120.82% sequentially from $28.6 million in Q4 2025.
Valneva SE (VALN) Interest Expenses (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has 7 years of Interest Expenses data on file, last reported at -$6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 5.21% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at $50.0 million (up 108.33% YoY), and the FY2025 full-year result was $48.8 million, up 87.76% from the prior year.
- Interest Expenses declined to -$6.0 million in Q1 2026, from $28.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $5.8 billion in Q3 2023 to a low of -$5.8 billion in Q2 2023.
- A 5-year average of $6.1 million and a median of -$2.5 million in 2022 frame the typical range for Interest Expenses.
- Peak annual rise in Interest Expenses reached 231663.58% in 2023, while the deepest fall reached 822382.75% in 2023.
- Tracing VALN's Interest Expenses over 5 years: stood at $26.1 million in 2022, then surged by 47.5% to $38.5 million in 2023, then plunged by 82.52% to $6.7 million in 2024, then surged by 325.35% to $28.6 million in 2025, then plunged by 120.82% to -$6.0 million in 2026.
- Business Quant data shows VALN's Interest Expenses at -$6.0 million in Q1 2026, $28.6 million in Q4 2025, and $31.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Valneva SE | 811.46 Mn | 688.23 Mn | 5.08 Mn | -5.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.96 Mn |
| Mar 31, 2026 | -5.96 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Sep 30, 2025 | 31.27 Mn |
| Sep 30, 2025 | 31.27 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 31.22 Mn |
| Sep 30, 2024 | 31.22 Mn |
| Jun 30, 2024 | -10.07 Mn |
| Jun 30, 2024 | -10.07 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Dec 31, 2023 | 38.52 Mn |
| Dec 31, 2023 | 38.52 Mn |